Profile data is unavailable for this security.
About the company
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
- Revenue in USD (TTM)103.27m
- Net income in USD-64.24m
- Incorporated2007
- Employees459.00
- LocationLifecore Biomedical Inc3515 Lyman BoulevardCHASKA 55318United StatesUSA
- Phone+1 (952) 368-4300
- Fax+1 (302) 636-5454
- Websitehttps://www.lifecore.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I-Mab ADR | 3.80m | -201.48m | 115.66m | 220.00 | -- | 0.4886 | -- | 30.44 | -2.42 | -2.42 | 0.0457 | 2.93 | 0.0083 | -- | -- | 17,272.58 | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -4.66 | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -18.84m | 119.33m | 1.00 | -- | 39.56 | -- | -- | -0.6889 | -0.6889 | 0.00 | 0.1019 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.8986 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Hongchang International Co Ltd | 2.67m | -365.80k | 129.71m | 8.00 | -- | 3.28 | -- | 48.64 | -0.0006 | -0.0006 | 0.0055 | 0.0763 | 0.0993 | -- | 175.86 | -- | -1.36 | -7.98 | -1.42 | -10.94 | 3.03 | 11.47 | -13.72 | -64.88 | 5.86 | -- | 0.2263 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Amylyx Pharmaceuticals Inc | 398.00m | -71.10m | 133.29m | 384.00 | -- | 0.4107 | -- | 0.3349 | -1.07 | -1.07 | 5.74 | 4.77 | 0.9644 | 6.74 | 21.00 | 1,036,461.00 | -17.23 | -- | -20.84 | -- | 88.93 | -- | -17.86 | -- | 4.48 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Biostem Technologies Inc | 58.01m | 159.39k | 136.36m | 67.00 | -- | 20.69 | 355.14 | 2.35 | -0.0865 | -0.0865 | 3.60 | 0.4064 | 2.38 | 5.17 | 2.78 | -- | 0.6536 | -- | 9.45 | -- | 94.16 | -- | 0.2748 | -- | 1.10 | 1.23 | 0.3959 | -- | -- | -- | -- | -- | -- | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 138.32m | 217.00 | -- | 1.02 | -- | 43.51 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| OptiNose Inc | 74.02m | -30.75m | 147.74m | 132.00 | -- | -- | -- | 2.00 | -0.2733 | -0.2733 | 0.659 | -0.8777 | 0.7453 | 0.8764 | 4.74 | 560,772.80 | -30.91 | -48.25 | -- | -98.95 | 88.98 | 86.96 | -41.47 | -131.66 | 2.17 | -1.16 | 4.16 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Assertio Holdings Inc | 142.05m | -332.97m | 154.10m | 53.00 | -- | 1.15 | -- | 1.08 | -3.95 | -3.95 | 1.66 | 1.41 | 0.4081 | 1.19 | 3.19 | 2,680,208.00 | -95.65 | -21.51 | -130.77 | -32.05 | 76.96 | 88.68 | -234.40 | -62.10 | 1.45 | -- | 0.2231 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
| Lifecore Biomedical Inc | 103.27m | -64.24m | 171.67m | 459.00 | -- | -- | -- | 1.66 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
| Scpharmaceuticals Inc | 17.63m | -57.71m | 177.39m | 135.00 | -- | 7.22 | -- | 10.06 | -1.49 | -1.49 | 0.4545 | 0.6814 | 0.1713 | 0.7566 | 4.02 | 130,607.40 | -56.07 | -38.23 | -62.13 | -42.31 | 71.69 | -- | -327.29 | -1,360.16 | 5.44 | -16.60 | 0.6159 | -- | -- | -- | -48.79 | -- | -- | -- |
| Mediwound Ltd | 19.85m | -12.75m | 182.42m | 100.00 | -- | 8.04 | -- | 9.19 | -1.38 | -1.38 | 2.15 | 2.44 | 0.303 | 5.64 | 5.07 | 198,510.00 | -19.46 | -24.48 | -25.65 | -32.92 | 16.92 | 43.27 | -64.24 | -38.43 | 1.83 | -- | 0.218 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Elite Pharmaceuticals Inc | 56.63m | 20.11m | 195.52m | 64.00 | 9.76 | 3.56 | 9.10 | 3.45 | 0.0197 | 0.0197 | 0.0554 | 0.0539 | 0.9093 | 2.69 | 5.02 | 884,767.80 | 32.29 | 19.07 | 38.79 | 24.29 | 46.55 | 46.63 | 35.51 | 20.77 | 2.08 | 1.70 | 0.1399 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
| ASP Isotopes Inc | 1.27m | -19.62m | 201.75m | 76.00 | -- | 14.14 | -- | 158.44 | -0.5335 | -0.5335 | 0.0344 | 0.2164 | 0.0425 | -- | -- | 16,755.00 | -65.49 | -- | -81.59 | -- | 32.81 | -- | -1,542.66 | -- | -- | -17.39 | 0.633 | -- | -- | -- | -229.34 | -- | -- | -- |
| Inhibrx Biosciences Inc | 1.78m | -271.16m | 206.28m | 166.00 | -- | 60.65 | -- | 115.69 | -5.35 | -5.35 | 0.0358 | 0.235 | 0.0066 | -- | 7.51 | 10,740.96 | -99.40 | -77.06 | -123.13 | -93.91 | -- | -- | -15,116.15 | -1,590.91 | -- | -12.67 | 0.9474 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Greenwich Lifesciences Inc | 0.00 | -9.24m | 206.60m | 3.00 | -- | 40.33 | -- | -- | -0.719 | -0.719 | 0.00 | 0.3977 | 0.00 | -- | -- | 0.00 | -106.03 | -36.43 | -109.97 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
Data as of Jul 24 2024. Currency figures normalised to Lifecore Biomedical Inc's reporting currency: US Dollar USD
51.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wynnefield Capital, Inc.as of 02 Jul 2024 | 4.41m | 14.44% |
| Legion Partners Asset Management LLCas of 08 Jul 2024 | 2.94m | 9.63% |
| Greenhaven Road Investment Management LPas of 31 Mar 2024 | 2.14m | 7.02% |
| 22NW LPas of 28 Jun 2024 | 1.76m | 5.75% |
| 325 Capital LLCas of 31 Mar 2024 | 1.34m | 4.39% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.17m | 3.84% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 627.70k | 2.06% |
| Visionary Wealth Advisors LLCas of 31 Mar 2024 | 496.78k | 1.63% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 460.45k | 1.51% |
| Millennium Management LLCas of 31 Mar 2024 | 352.71k | 1.16% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
